437 related articles for article (PubMed ID: 30127528)
1. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry.
Durbin AD; Zimmerman MW; Dharia NV; Abraham BJ; Iniguez AB; Weichert-Leahey N; He S; Krill-Burger JM; Root DE; Vazquez F; Tsherniak A; Hahn WC; Golub TR; Young RA; Look AT; Stegmaier K
Nat Genet; 2018 Sep; 50(9):1240-1246. PubMed ID: 30127528
[TBL] [Abstract][Full Text] [Related]
2. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.
Chen L; Alexe G; Dharia NV; Ross L; Iniguez AB; Conway AS; Wang EJ; Veschi V; Lam N; Qi J; Gustafson WC; Nasholm N; Vazquez F; Weir BA; Cowley GS; Ali LD; Pantel S; Jiang G; Harrington WF; Lee Y; Goodale A; Lubonja R; Krill-Burger JM; Meyers RM; Tsherniak A; Root DE; Bradner JE; Golub TR; Roberts CW; Hahn WC; Weiss WA; Thiele CJ; Stegmaier K
J Clin Invest; 2018 Jan; 128(1):446-462. PubMed ID: 29202477
[TBL] [Abstract][Full Text] [Related]
3. HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype.
Xu M; Sun M; Zhang X; Nguyen R; Lei H; Shern JF; Thiele CJ; Liu Z
Cancer Res; 2023 Mar; 83(5):686-699. PubMed ID: 36598365
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
[TBL] [Abstract][Full Text] [Related]
5. TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets.
Decaesteker B; Denecker G; Van Neste C; Dolman EM; Van Loocke W; Gartlgruber M; Nunes C; De Vloed F; Depuydt P; Verboom K; Rombaut D; Loontiens S; De Wyn J; Kholosy WM; Koopmans B; Essing AHW; Herrmann C; Dreidax D; Durinck K; Deforce D; Van Nieuwerburgh F; Henssen A; Versteeg R; Boeva V; Schleiermacher G; van Nes J; Mestdagh P; Vanhauwaert S; Schulte JH; Westermann F; Molenaar JJ; De Preter K; Speleman F
Nat Commun; 2018 Nov; 9(1):4866. PubMed ID: 30451831
[TBL] [Abstract][Full Text] [Related]
6. Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.
Rajbhandari P; Lopez G; Capdevila C; Salvatori B; Yu J; Rodriguez-Barrueco R; Martinez D; Yarmarkovich M; Weichert-Leahey N; Abraham BJ; Alvarez MJ; Iyer A; Harenza JL; Oldridge D; De Preter K; Koster J; Asgharzadeh S; Seeger RC; Wei JS; Khan J; Vandesompele J; Mestdagh P; Versteeg R; Look AT; Young RA; Iavarone A; Lasorella A; Silva JM; Maris JM; Califano A
Cancer Discov; 2018 May; 8(5):582-599. PubMed ID: 29510988
[TBL] [Abstract][Full Text] [Related]
7. SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma.
Tan K; Mo J; Li M; Dong Y; Han Y; Sun X; Ma Y; Zhu K; Wu W; Lu L; Liu J; Zhao K; Zhang L; Tang Y; Lv Z
J Exp Clin Cancer Res; 2022 Dec; 41(1):352. PubMed ID: 36539767
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.
Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F
Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123
[TBL] [Abstract][Full Text] [Related]
9. ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry.
Wang L; Tan TK; Durbin AD; Zimmerman MW; Abraham BJ; Tan SH; Ngoc PCT; Weichert-Leahey N; Akahane K; Lawton LN; Rokita JL; Maris JM; Young RA; Look AT; Sanda T
Nat Commun; 2019 Dec; 10(1):5622. PubMed ID: 31819055
[TBL] [Abstract][Full Text] [Related]
10. TAp63 represses transcription of MYCN/NCYM gene and its high levels of expression are associated with favorable outcome in neuroblastoma.
Suenaga Y; Yamamoto M; Sakuma T; Sasada M; Fukai F; Ohira M; Yamaguchi Y; Yamamoto T; Ando K; Ozaki T; Nakagawara A
Biochem Biophys Res Commun; 2019 Oct; 518(2):311-318. PubMed ID: 31427086
[TBL] [Abstract][Full Text] [Related]
11. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
12. LncRNA SNHG1 regulates neuroblastoma cell fate via interactions with HDAC1/2.
Hsu CL; Yin CF; Chang YW; Fan YC; Lin SH; Wu YC; Huang HC; Juan HF
Cell Death Dis; 2022 Sep; 13(9):809. PubMed ID: 36130928
[TBL] [Abstract][Full Text] [Related]
13. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
14. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
[TBL] [Abstract][Full Text] [Related]
15. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.
Zaatiti H; Abdallah J; Nasr Z; Khazen G; Sandler A; Abou-Antoun TJ
Int J Oncol; 2018 Mar; 52(3):787-803. PubMed ID: 29328367
[TBL] [Abstract][Full Text] [Related]
16. The KAT module of the SAGA complex maintains the oncogenic gene expression program in
Malone CF; Mabe NW; Forman AB; Alexe G; Engel KL; Chen YC; Soeung M; Salhotra S; Basanthakumar A; Liu B; Dent SYR; Stegmaier K
Sci Adv; 2024 May; 10(22):eadm9449. PubMed ID: 38820154
[TBL] [Abstract][Full Text] [Related]
17. Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification.
Wood L; Huang M; Zeki J; Gong M; Taylor J; Shimada H; Chiu B
J Pediatr Surg; 2021 Jul; 56(7):1199-1202. PubMed ID: 33838899
[TBL] [Abstract][Full Text] [Related]
18. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.
Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM
Cancer Res; 2018 Jun; 78(12):3122-3134. PubMed ID: 29610116
[TBL] [Abstract][Full Text] [Related]
19. Collaborative ISL1/GATA3 interaction in controlling neuroblastoma oncogenic pathways overlapping with but distinct from MYCN.
Zhang Q; Zhang Q; Jiang X; Ye Y; Liao H; Zhu F; Yan J; Luo L; Tian L; Jiang C; Chen Y; Liang X; Sun Y
Theranostics; 2019; 9(4):986-1000. PubMed ID: 30867811
[No Abstract] [Full Text] [Related]
20. Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma.
Hald ØH; Olsen L; Gallo-Oller G; Elfman LHM; Løkke C; Kogner P; Sveinbjörnsson B; Flægstad T; Johnsen JI; Einvik C
Oncogene; 2019 Apr; 38(15):2800-2813. PubMed ID: 30542116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]